Divi's Gears Up For A Biosimilars Play, Move Comes At The Back Of Demand From Existing Clients
This article was originally published in PharmAsia News
Executive Summary
HYDERABAD, India - Years of relationship with large multinational companies has prompted Divi's Labs - one of India's largest contract manufacturers for pharmaceutical raw materials or bulk drugs - to explore a presence in the biosimilars manufacturing space
You may also be interested in...
India and China Could Be On The Brink Of A Biosimilars Takeoff, Says One Biotech CEO
SINGAPORE - Asia's giants - India and China - could see a Big Bang-like explosion of biotech- and biosimilar-focused start-ups given the right conditions over the next decade, including an infusion of capital from the West, according to the head of an Indian biopharmaceutical firm
Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics
MUMBAI - Lucrative opportunities in the business of vaccines has attracted one more big drug maker. India's Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).